日
関

WordNet

the 8th letter of the Roman alphabet (同)h

PrepTutorEJDIC

hydrogenの化学記号
鉛筆の硬度 / 《俗》heroin

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/05/13 08:54:51」(JST)

wiki en

The 5-HT₇ receptor is a member of the GPCR superfamily of cell surface receptors and is activated by the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT)^[2] The 5-HT₇ receptor is coupled to G_s (stimulates the production of the intracellular signaling molecule cAMP)^[3]^[4] and is expressed in a variety of human tissues, particularly in the brain, the gastrointestinal tract, and in various blood vessels.^[4] This receptor has been a drug development target for the treatment of several clinical disorders.^[5] The 5-HT₇ receptor is encoded by the HTR7 gene, which in humans is transcribed into 3 different splice variants.^[6]

Function

When the 5-HT₇ receptor is activated by serotonin, it sets off a cascade of events starting with release of the stimulatory G protein G_s from the GPCR complex. G_s in turn activates adenylate cyclase which increases intracellular levels of the second messenger cAMP.

The 5-HT₇ receptor plays a role in smooth muscle relaxation within the vasculature and in the gastrointestinal tract.^[2] The highest 5-HT₇ receptor densities are in the thalamus and hypothalamus, and it is present at higher densities also in the hippocampus and cortex. The 5-HT₇ receptor is involved in thermoregulation, circadian rhythm, learning and memory, and sleep. It is also speculated that this receptor may be involved in mood regulation, suggesting that it may be a useful target in the treatment of depression.^[7]^[8]

Variants

Three splice variants have been identified in humans (designated h5-HT_7(a), h5-HT_7(b), and h5-HT_7(d)), which encode receptors that differ in their carboxy terminals.^[6] The h5-HT_7(a) is the full length receptor (445 amino acids),^[4] while the h5-HT_7(b) is truncated at amino acid 432 due to alternative splice donor site. The h5-HT_7(d) is a distinct isoform of the receptor: the retention of an exon cassette in the region encoding the carboxyl terminal results a 479-amino acid receptor with a c-terminus markedly different from the h5-HT_7(a). A 5-HT_7(c) splice variant is detectable in rat tissue but is not expressed in humans. Conversely, rats do not express a splice variant homologous to the h5-HT_7(d), as the rat 5-HT₇ gene lacks the exon necessary to encode this isoform.^[6] Drug binding affinities are similar across the three human splice variants;^[9] however, inverse agonist efficacies appear to differ between the splice variants.^[10]

Discovery

In 1983, evidence for a 5-HT₁-like receptor was first found.^[11] Ten years later, 5-HT₇ receptor was cloned and characterized.^[4] It has since become clear that the receptor described in 1983 is 5-HT₇.^[12]

Clinical significance

This receptor gene is a candidate locus for involvement in autistic disorder and other neuropsychiatric disorders.^[13]

Ligands

Numerous ligands bind to the 5-HT₇ receptor with moderate to high affinity.

Agonists

Agonists mimic the effects of the endogenous ligand, which is serotonin at the 5-HT₇ receptor (↑cAMP).

5-Carboxamidotryptamine (5-CT)
5-methoxytryptamine (5-MT, 5-MeOT)
8-OH-DPAT (mixed 5-HT_1A/5-HT₇ agonist)^[14]
Aripiprazole (weak partial agonist)^[15]
AS-19
E-55888^[16]
E-57431^[17]
LP-12 (4-(2-Diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide)
LP-44 (4-[2-(Methylthio)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-1-piperazinehexanamide)
LP-211
LSD
MSD-5a^[18]
N_ω-Methylserotonin^[19]
N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides (can function as either an agonist or antagonist depending on side chain substitution)^[20]^[21]
N,N-Dimethyltryptamine
RA-7 (1-(2-diphenyl)piperazine)

Antagonists

Neutral antagonists (also known as silent antagonists) bind the receptor and have no intrinsic activity but will block the activity of agonists or inverse agonists. Inverse agonists inhibit the constitutive activity of the receptor, producing functional effects opposite to those of agonists (at the 5-HT₇ receptor: ↓cAMP).^[22]^[23] Neutral antagonists and inverse agonists are typically referred to collectively as "antagonists" and, in the case of the 5-HT₇ receptor, differentiation between neutral antagonists and inverse agonists is problematic due to differing levels inverse agonist efficacy between receptor splice variants. For instance, mesulergine and metergoline are reported to be neutral antagonists at the h5-HT_7(a) and h5-HT_7(d) receptor isoforms but these drugs display marked inverse agonist effects at the h5-HT_7(b) splice variant.^[10]

3-{4-[4-(4-chlorophenyl)-piperazin-1-yl]-butyl}-3-ethyl-6-fluoro-1,3-dihydro-2H-indol-2-one^[24]
Amisulpride^[25]
Amitriptyline
Amoxapine
Clomipramine
Clozapine
DR-4485
EGIS-12233 (mixed 5-HT₆/5-HT₇ antagonist)
Fluphenazine
Fluperlapine
ICI 169,369
Imipramine
Ketanserin
Loxapine
Lurasidone
LY-215,840
Maprotiline
Mesulergine
Methysergide
Mianserin
Olanzapine
Pimozide
Ritanserin
SB-258,719^[26]^[27]^[28]
SB-258,741^[28]
SB-269,970 (highly 5-HT₇ selective)^[29]
SB-656,104-A^[30]
SB-691,673^[26]
Sertindole
Spiperone
Tenilapine
TFMPP
Vortioxetine
Trifluoperazine
Ziprasidone
Zotepine

Inactivating antagonists

Inactivating antagonists are non-competitive antagonists that render the receptor persistently insensitive to agonist, which resembles receptor desensitization. Inactivation of the 5-HT₇ receptor, however, does not arise from the classically described mechanisms of receptor desensitization via receptor phosphorylation, beta-arrestin recruitment, and receptor internalization.^[31] Inactivating antagonists all likely interact with the 5-HT₇ receptor in an irreversible/pseudo-irreversible manner, as is the case with [³H]risperidone.^[32]^[33]

Bromocriptine^[33]
Lisuride^[33]
Metergoline^[33]
Methiothepin^[32]
Paliperidone^[32]
Risperidone^[32]

References

^ "Snake-like view of 5ht7r_human". GPCRDB: Information system for G protein-coupled receptors. www.gpcr.org.
This diagram was created with the Residue-based Diagram generator (RbDg)
- Konvicka K, Campagne F, Weinstein H (June 2000). "Interactive construction of residue-based diagrams of proteins: the RbDe web service". Protein Eng. 13 (6): 395–6. doi:10.1093/protein/13.6.395. PMID 10877849.
- Skrabanek L, Campagne F, Weinstein H (July 2003). "Building protein diagrams on the web with the residue-based diagram editor RbDe". Nucleic Acids Res. 31 (13): 3856–8. doi:10.1093/nar/gkg552. PMC 168959. PMID 12824436. )
^ ^a ^b Vanhoenacker P, Haegeman G, Leysen JE (February 2000). "5-HT7 receptors: current knowledge and future prospects". Trends Pharmacol. Sci. 21 (2): 70–7. doi:10.1016/S0165-6147(99)01432-7. PMID 10664612.
^ Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, Schwartz JC (September 1993). "Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation". Proc. Natl. Acad. Sci. U.S.A. 90 (18): 8547–51. doi:10.1073/pnas.90.18.8547. PMC 47394. PMID 8397408.
^ ^a ^b ^c ^d Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL (November 1993). "Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase". J. Biol. Chem. 268 (31): 23422–6. PMID 8226867.
^ Mnie-Filali O, Lambás-Señas L, Zimmer L, Haddjeri N (December 2007). "5-HT7 receptor antagonists as a new class of antidepressants". Drug News Perspect. 20 (10): 613–8. doi:10.1358/dnp.2007.20.10.1181354. PMID 18301795.
^ ^a ^b ^c Heidmann DE, Metcalf MA, Kohen R, Hamblin MW (April 1997). "Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organization". J. Neurochem. 68 (4): 1372–81. doi:10.1046/j.1471-4159.1997.68041372.x. PMID 9084407.
^ Hedlund PB, Sutcliffe JG (September 2004). "Functional, molecular and pharmacological advances in 5-HT7 receptor research". Trends Pharmacol. Sci. 25 (9): 481–6. doi:10.1016/j.tips.2004.07.002. PMID 15559250.
^ Naumenko VS, Popova NK, Lacivita E, Leopoldo M, Ponimaskin EG (2014). "Interplay between Serotonin 5-HT1A and 5-HT7 Receptors in Depressive Disorders". CNS Neurosci Ther 20 (7): 582–90. doi:10.1111/cns.12247. PMID 24935787.
^ Krobert KA, Bach T, Syversveen T, Kvingedal AM and Levy FO (2001) The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution. Naunyn Schmiedebergs Arch Pharmacol 363(6):620-632. (2001). "The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution.". Naunyn-Schmiedeberg's archives of pharmacology 363 (6): 620–32. doi:10.1007/s002100000369. PMID 11414657.
^ ^a ^b Krobert KA and Levy FO (2002) The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects. Br J Pharmacol 135(6):1563-1571. (2002). "The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.". British Journal of Pharmacology 135 (6): 1563–71. doi:10.1038/sj.bjp.0704588. PMC 1573253. PMID 11906971.
^ Feniuk, W.; Humphrey, P. P.; Watts, A. D. (1983). "5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle". European Journal of Pharmacology 96 (1–2): 71–78. doi:10.1016/0014-2999(83)90530-7. PMID 6662198.
^ Hoyer, D.; Hannon, J. P.; Martin, G. R. (2002). "Molecular, pharmacological and functional diversity of 5-HT receptors". Pharmacology, Biochemistry, and Behavior 71 (4): 533–554. doi:10.1016/S0091-3057(01)00746-8. PMID 11888546.
^ Lassig JP, Vachirasomtoon K, Hartzell K, Leventhal M, Courchesne E, Courchesne R, Lord C, Leventhal BL, Cook EH (October 1999). "Physical mapping of the serotonin 5-HT(7) receptor gene (HTR7) to chromosome 10 and pseudogene (HTR7P) to chromosome 12, and testing of linkage disequilibrium between HTR7 and autistic disorder". Am. J. Med. Genet. 88 (5): 472–5. doi:10.1002/(SICI)1096-8628(19991015)88:5<472::AID-AJMG7>3.0.CO;2-G. PMID 10490701.
^ Sprouse J, Reynolds L, Li X, Braselton J, Schmidt A (2004). "8-OH-DPAT as a 5-HT₇ agonist: phase shifts of the circadian biological clock through increases in cAMP production". Neuropharmacology 46 (1): 52–62. doi:10.1016/j.neuropharm.2003.08.007. PMID 14654097.
^ Davies MA, Sheffler DJ, Roth BL. Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology. CNS Drug Reviews [Internet]. 2004 [cited 2013 Aug 4];10(4):317–36. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00030.x/pdf
^ Brenchat A, Ejarque M, Zamanillo D, Vela JM, Romero L (August 2011). "Potentiation of Morphine Analgesia by Adjuvant Activation of 5-HT(7) Receptors". Journal of Pharmacological Sciences 116 (4): 388–91. doi:10.1254/jphs.11039sc. PMID 21778664.
^ Brenchat A, Nadal X, Romero L, Ovalle S, Muro A, Sánchez-Arroyos R, Portillo-Salido E, Pujol M, Montero A, Codony X, Burgueño J, Zamanillo D, Hamon M, Maldonado R, Vela JM (June 2010). "Pharmacological activation of 5-HT7 receptors reduces nerve injury-induced mechanical and thermal hypersensitivity". Pain 149 (3): 483–94. doi:10.1016/j.pain.2010.03.007. PMID 20399562.
^ Brenchat A, Romero L, García M, Pujol M, Burgueño J, Torrens A, Hamon M, Baeyens JM, Buschmann H, Zamanillo D, Vela JM (February 2009). "5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice". Pain 141 (3): 239–47. doi:10.1016/j.pain.2008.11.009. PMID 19118950.
^ Powell SL, Gödecke T, Nikolic D, Chen SN, Ahn S, Dietz B, Farnsworth NR, van Breemen RB, Lankin DC, Pauli GF, Bolton JL (2008). "In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent". J Agric Food Chem 56 (24): 1718–1726. doi:10.1021/jf803298z. PMID 19049296.
^ Leopoldo M, Lacivita E, Contino M, Colabufo NA, Berardi F, Perrone R (2007). "Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT₇ receptor agents. 2". J. Med. Chem. 50 (17): 4214–21. doi:10.1021/jm070487n. PMID 17649988.
^ Leopoldo M, Berardi F, Colabufo NA; et al. (2004). "Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents". J. Med. Chem. 47 (26): 6616–24. doi:10.1021/jm049702f. PMID 15588097.
^ Pittalà V, Salerno L, Modica M, Siracusa MA, Romeo G (2007). "5-HT7 receptor ligands: recent developments and potential therapeutic applications". Mini Rev Med Chem 7 (9): 945–60. doi:10.2174/138955707781662663. PMID 17897083.
^ Leopoldo M (2004). "Serotonin(7) receptors (5-HT(7)Rs) and their ligands". Curr. Med. Chem. 11 (5): 629–61. doi:10.2174/0929867043455828. PMID 15032609.
^ Volk B, Barkóczy J, Hegedus E; et al. (April 2008). "(Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists". J. Med. Chem. 51 (8): 2522–32. doi:10.1021/jm070279v. PMID 18361484.
^ Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (July 2009). "Amisulpride is a potent 5-HT₇ antagonist: relevance for antidepressant actions in vivo". Psychopharmacology (Berl.) 205 (1): 119–28. doi:10.1007/s00213-009-1521-8. PMC 2821721. PMID 19337725.
^ ^a ^b Romero G, Pujol M, Pauwels PJ (2006). "Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists". Naunyn Schmiedebergs Arch. Pharmacol. 374 (1): 31–9. doi:10.1007/s00210-006-0093-y. PMID 16967291.
^ Forbes IT, Dabbs S, Duckworth DM; et al. (February 1998). "(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist". J. Med. Chem. 41 (5): 655–7. doi:10.1021/jm970519e. PMID 9513592.
^ ^a ^b Mahé C, Loetscher E, Feuerbach D, Müller W, Seiler MP, Schoeffter P (2004). "Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors". Eur. J. Pharmacol. 495 (2-3): 97–102. doi:10.1016/j.ejphar.2004.05.033. PMID 15249157.
^ Lovell PJ, Bromidge SM, Dabbs S, Duckworth DM, Forbes IT, Jennings AJ, King FD, Middlemiss DN, Rahman SK, Saunders DV, Collin LL, Hagan JJ, Riley GJ and Thomas DR (2000) A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970) (2000). "A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).". Journal of Medicinal Chemistry 43 (3): 342–5. doi:10.1021/jm991151j. PMID 10669560.
^ Forbes IT, Douglas S, Gribble AD; et al. (November 2002). "SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties". Bioorg. Med. Chem. Lett. 12 (22): 3341–4. doi:10.1016/S0960-894X(02)00690-X. PMID 12392747.
^ Zhang J, Ferguson SS, Barak LS, Aber MJ, Giros B, Lefkowitz RJ and Caron MG (1997) Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization. Receptors Channels 5(3-4):193-199. (1997). "Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization.". Receptors & channels 5 (3-4): 193–9. PMID 9606723.
^ ^a ^b ^c ^d Smith C, Rahman T, Toohey N, Mazurkiewicz J, Herrick-Davis K and Teitler M (2006) Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor. Mol Pharmacol 70(4):1264-1270. (2006). "Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor.". Molecular Pharmacology 70 (4): 1264–70. doi:10.1124/mol.106.024612. PMID 16870886.
^ ^a ^b ^c ^d Knight JA, Smith C, Toohey N, Klein MT and Teitler M (2009) Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists. Mol Pharmacol 75(2):374-380. (2009). "Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists.". Molecular Pharmacology 75 (2): 374–80. doi:10.1124/mol.108.052084. PMC 2671286. PMID 18996971.

External links

"5-HT₇". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 統合失調症に対するクロザピン投与のガイドライン guidelines for prescribing clozapine in schizophrenia
2. 原発性両側副腎皮質大結節性過形成によるクッシング症候群 cushings syndrome due to primary bilateral macronodular adrenal hyperplasia

English Journal

Rational site-directed pharmacotherapy for major depressive disorder.

Blier P.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP).Int J Neuropsychopharmacol.2014 Jul;17(7):997-1008. doi: 10.1017/S1461145713000400. Epub 2013 Jun 10.
It is now accepted that major depressive disorder (MDD) is not a single pathophysiological entity. It is therefore not surprising that remission rates to a first antidepressant trial are low. In addition, antidepressants may target various neuronal elements for which there are gene polymorphisms, su
PMID 23745670

Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties.

Spadoni G1, Bedini A1, Bartolucci S1, Pala D2, Mor M2, Riccioni T3, Borsini F3, Cabri W3, Celona D3, Marzi M3, Tarzia G1, Rivara S4, Minetti P5.
European journal of medicinal chemistry.Eur J Med Chem.2014 Jun 10;80:8-35. doi: 10.1016/j.ejmech.2014.04.034. Epub 2014 Apr 13.
Many known 5-HT7 ligands contain either a serotonin-like or an arylpiperazine structure that, in published SAR studies, are generally supposed to bind the same receptor pocket. Conversely, we explored the hypothesis that two such moieties can co-exist in the same ligand, binding to different pockets
PMID 24763360

Vortioxetine for the treatment of depression.

Pearce EF1, Murphy JA.
The Annals of pharmacotherapy.Ann Pharmacother.2014 Jun;48(6):758-65. doi: 10.1177/1060028014528305. Epub 2014 Mar 27.
OBJECTIVE: To evaluate the clinical literature and potential clinical role of vortioxetine (Brintellix) for the treatment of major depressive disorder (MDD).DATA SOURCES: A MEDLINE search (1966-February 2014) was conducted using the search terms vortioxetine, Lu AA21004, and depression. Bibliographi
PMID 24676550

Japanese Journal

抑肝散の活性成分ガイソシジンメチルエーテルの薬理作用と血液脳関門透過性に関する研究

福岡大学薬学集報 15(0), 1-8, 2015-03
NAID 110009882351

Serotonin Regulates β-Casein Expression via 5-HT₇ Receptors in Human Mammary Epithelial MCF-12A Cells

Biological and Pharmaceutical Bulletin 38(3), 448-453, 2015
NAID 130004872286

Role of Serotonin 5-HT₃ Receptors in Intestinal Inflammation (Recent Advances in 5-Hydroxytryptamine (5-HT) Receptor Research : How Many Pathophysiological Roles Does 5-HT Play via Its Multiple Receptor Subtypes?)

Biological and Pharmaceutical Bulletin 36(9), 1406-1409, 2013
NAID 130003361527

Related Pictures

★リンクテーブル★

「HT」

5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled
Identifiers
Symbols	HTR7 ; 5-HT7
External IDs	OMIM: 182137 MGI: 99841 HomoloGene: 20244 IUPHAR: 12 ChEMBL: 3155 GeneCards: HTR7 Gene
Gene ontology
Molecular function	• serotonin receptor activity;
Cellular component	• plasma membrane; • integral component of plasma membrane;
Biological process	• smooth muscle contraction; • G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; • serotonin receptor signaling pathway; • synaptic transmission; • circadian rhythm; • blood circulation; • vasoconstriction;
	Sources: Amigo / QuickGO
RNA expression pattern
	More reference expression data
Orthologs
	v; t; e;

　　[★]

「H」

　　[★]

[urlwww.gpcr.org-1] "Snake-like view of 5ht7r_human". GPCRDB: Information system for G protein-coupled receptors. www.gpcr.org.

This diagram was created with the Residue-based Diagram generator (RbDg)

Konvicka K, Campagne F, Weinstein H (June 2000). "Interactive construction of residue-based diagrams of proteins: the RbDe web service". Protein Eng. 13 (6): 395–6. doi:10.1093/protein/13.6.395. PMID 10877849.

Skrabanek L, Campagne F, Weinstein H (July 2003). "Building protein diagrams on the web with the residue-based diagram editor RbDe". Nucleic Acids Res. 31 (13): 3856–8. doi:10.1093/nar/gkg552. PMC 168959. PMID 12824436. )

[2] Konvicka K, Campagne F, Weinstein H (June 2000). "Interactive construction of residue-based diagrams of proteins: the RbDe web service". Protein Eng. 13 (6): 395–6. doi:10.1093/protein/13.6.395. PMID 10877849.

[3] Skrabanek L, Campagne F, Weinstein H (July 2003). "Building protein diagrams on the web with the residue-based diagram editor RbDe". Nucleic Acids Res. 31 (13): 3856–8. doi:10.1093/nar/gkg552. PMC 168959. PMID 12824436. )

[pmid10664612-2] Vanhoenacker P, Haegeman G, Leysen JE (February 2000). "5-HT7 receptors: current knowledge and future prospects". Trends Pharmacol. Sci. 21 (2): 70–7. doi:10.1016/S0165-6147(99)01432-7. PMID 10664612.

[pmid8397408-3] Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, Schwartz JC (September 1993). "Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation". Proc. Natl. Acad. Sci. U.S.A. 90 (18): 8547–51. doi:10.1073/pnas.90.18.8547. PMC 47394. PMID 8397408.

[pmid8226867-4] Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL (November 1993). "Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase". J. Biol. Chem. 268 (31): 23422–6. PMID 8226867.

[pmid18301795-5] Mnie-Filali O, Lambás-Señas L, Zimmer L, Haddjeri N (December 2007). "5-HT7 receptor antagonists as a new class of antidepressants". Drug News Perspect. 20 (10): 613–8. doi:10.1358/dnp.2007.20.10.1181354. PMID 18301795.

[pmid9084407-6] Heidmann DE, Metcalf MA, Kohen R, Hamblin MW (April 1997). "Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organization". J. Neurochem. 68 (4): 1372–81. doi:10.1046/j.1471-4159.1997.68041372.x. PMID 9084407.

[pmid15559250-7] Hedlund PB, Sutcliffe JG (September 2004). "Functional, molecular and pharmacological advances in 5-HT7 receptor research". Trends Pharmacol. Sci. 25 (9): 481–6. doi:10.1016/j.tips.2004.07.002. PMID 15559250.

[8] Naumenko VS, Popova NK, Lacivita E, Leopoldo M, Ponimaskin EG (2014). "Interplay between Serotonin 5-HT1A and 5-HT7 Receptors in Depressive Disorders". CNS Neurosci Ther 20 (7): 582–90. doi:10.1111/cns.12247. PMID 24935787.

[pmid11414657-9] Krobert KA, Bach T, Syversveen T, Kvingedal AM and Levy FO (2001) The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution. Naunyn Schmiedebergs Arch Pharmacol 363(6):620-632. (2001). "The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution.". Naunyn-Schmiedeberg's archives of pharmacology 363 (6): 620–32. doi:10.1007/s002100000369. PMID 11414657.

[pmid11906971-10] Krobert KA and Levy FO (2002) The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects. Br J Pharmacol 135(6):1563-1571. (2002). "The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.". British Journal of Pharmacology 135 (6): 1563–71. doi:10.1038/sj.bjp.0704588. PMC 1573253. PMID 11906971.

[11] Feniuk, W.; Humphrey, P. P.; Watts, A. D. (1983). "5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle". European Journal of Pharmacology 96 (1–2): 71–78. doi:10.1016/0014-2999(83)90530-7. PMID 6662198.

[12] Hoyer, D.; Hannon, J. P.; Martin, G. R. (2002). "Molecular, pharmacological and functional diversity of 5-HT receptors". Pharmacology, Biochemistry, and Behavior 71 (4): 533–554. doi:10.1016/S0091-3057(01)00746-8. PMID 11888546.

[pmid10490701-13] Lassig JP, Vachirasomtoon K, Hartzell K, Leventhal M, Courchesne E, Courchesne R, Lord C, Leventhal BL, Cook EH (October 1999). "Physical mapping of the serotonin 5-HT(7) receptor gene (HTR7) to chromosome 10 and pseudogene (HTR7P) to chromosome 12, and testing of linkage disequilibrium between HTR7 and autistic disorder". Am. J. Med. Genet. 88 (5): 472–5. doi:10.1002/(SICI)1096-8628(19991015)88:5<472::AID-AJMG7>3.0.CO;2-G. PMID 10490701.

[pmid14654097-14] Sprouse J, Reynolds L, Li X, Braselton J, Schmidt A (2004). "8-OH-DPAT as a 5-HT₇ agonist: phase shifts of the circadian biological clock through increases in cAMP production". Neuropharmacology 46 (1): 52–62. doi:10.1016/j.neuropharm.2003.08.007. PMID 14654097.

[15] Davies MA, Sheffler DJ, Roth BL. Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology. CNS Drug Reviews [Internet]. 2004 [cited 2013 Aug 4];10(4):317–36. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00030.x/pdf

[pmid21778664-16] Brenchat A, Ejarque M, Zamanillo D, Vela JM, Romero L (August 2011). "Potentiation of Morphine Analgesia by Adjuvant Activation of 5-HT(7) Receptors". Journal of Pharmacological Sciences 116 (4): 388–91. doi:10.1254/jphs.11039sc. PMID 21778664.

[pmid20399562-17] Brenchat A, Nadal X, Romero L, Ovalle S, Muro A, Sánchez-Arroyos R, Portillo-Salido E, Pujol M, Montero A, Codony X, Burgueño J, Zamanillo D, Hamon M, Maldonado R, Vela JM (June 2010). "Pharmacological activation of 5-HT7 receptors reduces nerve injury-induced mechanical and thermal hypersensitivity". Pain 149 (3): 483–94. doi:10.1016/j.pain.2010.03.007. PMID 20399562.

[pmid19118950-18] Brenchat A, Romero L, García M, Pujol M, Burgueño J, Torrens A, Hamon M, Baeyens JM, Buschmann H, Zamanillo D, Vela JM (February 2009). "5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice". Pain 141 (3): 239–47. doi:10.1016/j.pain.2008.11.009. PMID 19118950.

[Powell_et_al.-19] Powell SL, Gödecke T, Nikolic D, Chen SN, Ahn S, Dietz B, Farnsworth NR, van Breemen RB, Lankin DC, Pauli GF, Bolton JL (2008). "In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent". J Agric Food Chem 56 (24): 1718–1726. doi:10.1021/jf803298z. PMID 19049296.

[pmid17649988-20] Leopoldo M, Lacivita E, Contino M, Colabufo NA, Berardi F, Perrone R (2007). "Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT₇ receptor agents. 2". J. Med. Chem. 50 (17): 4214–21. doi:10.1021/jm070487n. PMID 17649988.

[pmid15588097-21] Leopoldo M, Berardi F, Colabufo NA; et al. (2004). "Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents". J. Med. Chem. 47 (26): 6616–24. doi:10.1021/jm049702f. PMID 15588097.

[pmid17897083-22] Pittalà V, Salerno L, Modica M, Siracusa MA, Romeo G (2007). "5-HT7 receptor ligands: recent developments and potential therapeutic applications". Mini Rev Med Chem 7 (9): 945–60. doi:10.2174/138955707781662663. PMID 17897083.

[pmid15032609-23] Leopoldo M (2004). "Serotonin(7) receptors (5-HT(7)Rs) and their ligands". Curr. Med. Chem. 11 (5): 629–61. doi:10.2174/0929867043455828. PMID 15032609.

[pmid18361484-24] Volk B, Barkóczy J, Hegedus E; et al. (April 2008). "(Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists". J. Med. Chem. 51 (8): 2522–32. doi:10.1021/jm070279v. PMID 18361484.

[pmid19337725-25] Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (July 2009). "Amisulpride is a potent 5-HT₇ antagonist: relevance for antidepressant actions in vivo". Psychopharmacology (Berl.) 205 (1): 119–28. doi:10.1007/s00213-009-1521-8. PMC 2821721. PMID 19337725.

[pmid16967291-26] Romero G, Pujol M, Pauwels PJ (2006). "Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists". Naunyn Schmiedebergs Arch. Pharmacol. 374 (1): 31–9. doi:10.1007/s00210-006-0093-y. PMID 16967291.

[pmid9513592-27] Forbes IT, Dabbs S, Duckworth DM; et al. (February 1998). "(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist". J. Med. Chem. 41 (5): 655–7. doi:10.1021/jm970519e. PMID 9513592.

[pmid15249157-28] Mahé C, Loetscher E, Feuerbach D, Müller W, Seiler MP, Schoeffter P (2004). "Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors". Eur. J. Pharmacol. 495 (2-3): 97–102. doi:10.1016/j.ejphar.2004.05.033. PMID 15249157.

[pmid10669560-29] Lovell PJ, Bromidge SM, Dabbs S, Duckworth DM, Forbes IT, Jennings AJ, King FD, Middlemiss DN, Rahman SK, Saunders DV, Collin LL, Hagan JJ, Riley GJ and Thomas DR (2000) A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970) (2000). "A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).". Journal of Medicinal Chemistry 43 (3): 342–5. doi:10.1021/jm991151j. PMID 10669560.

[pmid12392747-30] Forbes IT, Douglas S, Gribble AD; et al. (November 2002). "SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties". Bioorg. Med. Chem. Lett. 12 (22): 3341–4. doi:10.1016/S0960-894X(02)00690-X. PMID 12392747.

[pmid9606723-31] Zhang J, Ferguson SS, Barak LS, Aber MJ, Giros B, Lefkowitz RJ and Caron MG (1997) Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization. Receptors Channels 5(3-4):193-199. (1997). "Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization.". Receptors & channels 5 (3-4): 193–9. PMID 9606723.

[pmid16870886-32] Smith C, Rahman T, Toohey N, Mazurkiewicz J, Herrick-Davis K and Teitler M (2006) Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor. Mol Pharmacol 70(4):1264-1270. (2006). "Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor.". Molecular Pharmacology 70 (4): 1264–70. doi:10.1124/mol.106.024612. PMID 16870886.

[pmid18996971-33] Knight JA, Smith C, Toohey N, Klein MT and Teitler M (2009) Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists. Mol Pharmacol 75(2):374-380. (2009). "Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists.". Molecular Pharmacology 75 (2): 374–80. doi:10.1124/mol.108.052084. PMC 2671286. PMID 18996971.

匿名

検索

案内

案内

5-HT7